Get the Stockscreener App
0.4988
4.08%
-0.0212
Tenaya Therapeutics Inc stock is traded at $0.4988, with a volume of 2.12M.
It is down -4.08% in the last 24 hours and up +13.36% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$0.52
Open:
$0.5095
24h Volume:
2.12M
Relative Volume:
0.72
Market Cap:
$81.10M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.3779
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
-22.35%
1M Performance:
+13.36%
6M Performance:
-71.82%
1Y Performance:
-89.11%
1-Day Range:
$0.4834
$0.5196
1-Week Range:
$0.4834
$0.65
52-Week Range:
$0.4054
$4.96
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.4988 | 81.10M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo
Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance
Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st
Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener
Tenaya reports promising gene therapy for heart condition - Investing.com India
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire
Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan
Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN
Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener
Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World
Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World
Chardan Capital Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $9.00 - Defense World
What is HC Wainwright’s Estimate for TNYA Q1 Earnings? - Defense World
Canaccord cuts Tenaya Therapeutics price target to $6 By Investing.com - Investing.com South Africa
Canaccord cuts Tenaya Therapeutics price target to $6 - Investing.com
Q1 Earnings Forecast for TNYA Issued By Lifesci Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Chardan Adjusts Price Target on Tenaya Therapeutics to $9 From $18, Keeps Buy Rating - Marketscreener.com
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 By Investing.com - Investing.com Canada
Tenaya Therapeutics Advances Gene Therapy Pipeline - TipRanks
H.C. Wainwright cuts Tenaya Therapeutics price target to $5 - Investing.com
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
Tenaya Therapeutics SVP sells shares worth $1,334 By Investing.com - Investing.com Australia
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 By Investing.com - Investing.com Australia
Tenaya Therapeutics chief medical officer sells shares worth $3,982 By Investing.com - Investing.com South Africa
Tenaya Therapeutics chief medical officer sells shares worth $3,982 - Investing.com India
Tenaya Therapeutics CEO Ali Faraz sells shares worth $5,244 - Investing.com India
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):